Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer
Status:
Recruiting
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
GTI-4711-201 is designed as a Phase 2b, multicenter, randomized, double-blind,
placebo-controlled study to determine the effect to OS by adding GC4711 to SBRT following
chemotherapy in patients with unresectable or borderline resectable nonmetastatic